Welcome!

News Feed Item

Neurostimulation: Technologies and Global Markets

NEW YORK, April 9, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Neurostimulation: Technologies and Global Markets

http://www.reportlinker.com/p02070063/Neurostimulation-Technologies-and-...

 

REPORT HIGHLIGHTS

 

The global neurostimulation devices market is expected to reach $3.8 billion in 2013 and $4.1 billion in 2018, with a compound annual growth rate (CAGR) of 1.5%.

 

This report provides:

 

 

An overview of the global market for neurostimulation devices, many of which currently are in clinical trials or undergoing development to treat a range of disorders, including epilepsy, obesity, Parkinson's disease, depression, sexual dysfunction, urinary tract disorders, and drug addiction

Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018

A focus on individual disorders and variety of neurostimulation options, which include deep brain stimulation, transcranial magnetic brain stimulation, spinal cord stimulation, vagal nerve stimulation, sacral nerve stimulation, occipital nerve stimulation, tibial nerve stimulation, gastric electrical stimulation, and closed-loop/responsive stimulation

Examination of positive market impacts, which include increasing acceptance of neurostimulation devices for multiple applications, an aging population market, and technological advancements; as well as negative impacts, which include current device recalls, risks of neurostimulation devices, and investment and funding for new technological advancements

Evaluations of new product launches, current promising clinical trials, and the patent/technological pipeline

Comprehensive company profiles of major players.

 

INTRODUCTION

 

Neurostimulation incorporates technological advancements from a variety of fields including science, medicine and bioengineering. The main goal through these technologies is to develop implantable electrical devices to improve the quality of human life and day-to-day human functioning. This involves the process of electrically inhibiting or activating the functioning of the peripheral, central or autonomic nervous systems. The earliest implantable neurostimulation devices were spinal cord stimulators and stimulators to treat cardiovascular disease. In the 1970s, deep brain stimulator devices were introduced. It was around this time that the U.S. Food and Drug Administration (FDA) required implantable devices to be regulated and compliable with patient safety measures. From the 1980s to today, neurostimulators have been mainly used to treat movement disorders.

 

The neurostimulation device industry has seen rapid growth in the past decade. These technological advancements have not only led to improvements in existing neurostimulation devices, but they have also aided the development of the next generation of devices.Neurostimulation devices are increasingly used for pain management. Each year it is estimated that over 100 million people globally suffer from chronic pain. Currently drug therapies are the primary treatment option; however, in the long run these therapies have proved to be ineffective. As a result, in the current neurostimulation industry devices are of increasing interest for treating chronic pain. Recently a large number of neurostimulation devices have begun clinical trials or are undergoing development to treat a range of disorders including: epilepsy, obesity, Parkinson's disease, depression, sexual dysfunction, cardiovascular disorders, movement disorders, gastrointestinal disorders, urinary tract disorders, sensory disorders and drug addiction. This opens up a wider market of applications for neurostimulation devices.

 

This also points to the fact that a wide variety of clinical specialists, apart from neurosurgeons and neurologists, would be interested in applying the therapies enabled by neurostimulation.Currently, the market is underdeveloped despite technological advances due to low medical acceptance and equally low consumer awareness. Patients still fear the prospect of having a foreign object implanted into their bodies. This is anticipated to change with the commercialization of technologically advanced neurostimulators, physician training, increased venture capital and government funding and considerably due to the expansion of health insurance to the underinsured and uninsured. It should be noted that even with the expansion of health insurance, often health insurance providers do not offer full reimbursement for neurostimulation devices.

 

This is due to some providers being ill-informed and not being fully clear on the concept of neurostimulation as a viable treatment option. It becomes a priority for leading medical device manufacturers and physicians to inform insurance providers about the benefits and success stories of neurostimulation devices. This will lead to the successful implementation of neurostimulation devices on the market from manufacturing to implantation and through patient therapy.

 

STUDY GOALS AND OBJECTIVES

 

This report, Neurostimulation, from BCC Research includes forecasted trends and sales through 2018. Current market leaders, new technologies and factors influencing low and high demand are discussed. Neurostimulation ranges from noninvasive to minimally invasive to fully invasive. Depending upon the application, various neurostimulation devices are currently on the market.

 

This report is particularly focused on individual disorders and discusses a variety of neurostimulation options for each disorder—including deep brain stimulation, transcranial magnetic brain stimulation, spinal cord stimulation, vagal nerve stimulation, sacral nerve stimulation, occipital nerve stimulation, tibial nerve stimulation, gastric electrical stimulation and closed-loop/responsive stimulation. Finally, the report includes information about market share, new product launches, promising technologies and current clinical trials.

 

REASONS FOR DOING THE STUDY

 

As of 2011, the size of the neurostimulation market was estimated at 4.2 billion. This market serves a patient population with both sensory and motor neural deficits. Compared to other medical device markets, the neurostimulation market can still be considered as an emerging market. At this point in time, the exiting neurostimulation technologies of spinal cord stimulation, cochlear implants and vagal nerve stimulation are widely successful. The success of these technologies with current advances in imaging technologies can provide an increase in the number of clinical applications for neurostimulation devices. These applications will also increase with the establishment of specialized medical training and a patient population eligible to benefit from the neurostimulation devices.In the past few years, these advances have led to the development of a large number of small start-up firms working on exciting new technologies. This has created a competitive market place. This report will provide the reader with an overview of neurostimulation devices available for treating individual disorders along with an overview of company profiles.

 

SCOPE OF REPORT

 

This report is a business tool that primarily will be helpful in examining trends in the market for neurostimulation devices. It begins with an overview of neurostimulation devices, key players, entry-level players, market trend analysis and factors influencing future incidence. It will also include market analysis by clinical disorder, including annual incidence, trend analysis and factors influencing future predicted surgical volume. Finally, the report will cover market share and information on key neurostimulation device manufacturers.

 

INTENDED AUDIENCE

 

This report is intended for anyone interested in better understanding the role of the rapidly growing neurostimulation technologies of the broader neuromodulation markets.Executives, consultants, trade associations, clinicians and marketing professionals in the medical device industry, health insurance industry and experts in the neuroscience and neurosurgery fields would benefit from this report. Additionally, stock analysts, venture capitalists funders and investors focused on the neuromodulation markets or those who are interested in expanding markets for neurostimulation devices would also benefit. Manufacturers and distributors of the neurostimulation technologies discussed in this report are also an intended audience.

Chapter- 1: INTRODUCTION 4

 

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THE STUDY

SCOPE OF REPORT

INTENDED AUDIENCE

INFORMATION SOURCES

ANALYST CREDENTIALS

RELATED BCC RESEARCH REPORTS

BCC RESEARCH ONLINE SERVICES

DISCLAIMER

 

Chapter- 2: SUMMARY 3

 

GLOBAL FORECAST OF NEUROSTIMULATION DEVICES BY DISORDER CATEGORY THROUGH 2018

Figure 0 A : DISTRIBUTION OF NEUROSTIMULATION DEVICES BY TYPE OF DISORDER CATEGORY 2012-2018

Figure 0 B : GLOBAL FORECAST OF NEUROSTIMULATION DEVICES BY DISORDER CATEGORY 2012-2018

 

Chapter- 3: OVERVIEW OF NEUROSTIMULATION DEVICES

 

MARKET TRENDS (TECHNOLOGIES) AND MARKET SHARE (KEY PLAYERS AND ENTRY LEVEL)

POSITIVE MARKET IMPACT

NEGATIVE MARKET IMPACT

 

Chapter- 4: MARKET FOR NEUROSTIMULATION DEVICES

 

NEUROSTIMULATION FOR PAIN MANAGEMENT

NEUROSTIMULATION FOR MOVEMENT DISORDERS

NEUROSTIMULATION FOR NEUROPSYCHIATRIC DISORDERS

NEUROSTIMULATION FOR STROKE AND TRAUMATIC BRAIN INJURY

NEUROSTIMULATION FOR CARDIOVASCULAR DISORDERS

NEUROSTIMULATION FOR GASTROINTESTINAL DISORDERS

NEUROSTIMULATION FOR URINARY AND RECTAL DISORDERS

NEUROSTIMULATION FOR SENSORY DISORDERS

ADAPTIVE NEUROSTIMULATION THERAPY

 

Chapter- 5: COMPANY PROFILES

 

ADVANCED BIONICS, LLC

ALEVA NEUROTHERAPEUTICS SA

ATROTECH OY

AUTONOMIC TECHNOLOGIES INC.

AVERY BIOMEDICAL DEVICES, INC.

BIONESS INC.

BIOTRONIK SE & CO.KG

BOSTON SCIENTIFIC CORPORATION

CERBOMED GMBH

COCHLEAR AMERICAS

CVRX INC.

CYBERONICS, INC.

ENTEROMEDICS INC.

MED-EL MEDICAL ELECTRONICS

MEDTRONIC, INC.

NEUROMETRIX INC.

NEURONETICS, INC.

NEUROPACE INC.

NEUROSIGMA

NEVRO CORPORATION

SECOND SIGHT MEDICAL PRODUCTS, INC.

SPINAL MODULATION INC.

SPR THERAPEUTICS LLC

ST. JUDE MEDICAL

UROPLASTY, INC.

ZYNEX MEDICAL, INC.

 

 

List of Tables

 

GLOBAL FORECAST OF NEUROSTIMULATION DEVICES BY DISORDER CATEGORY THROUGH 2018

Table 1 : MARKET SHARE OF CHRONIC PAIN DEVICE MANUFACTURERS

Table 2 : MARKET SHARE OF CHRONIC PAIN DEVICE MANUFACTURERS

Table 3 : HEARING LOSS DEVICE GLOBAL MARKET DISTRIBUTION

Table 4 : MANUFACTURERS OF HEARING LOSS DEVICES MARKET SHARE

Table 5 : MANUFACTURERS OF OVERACTIVE BLADDER DEVICES MARKET SHARE IN NORTH AMERICA

Table 6 : MARKET SHARE OF MANUFACTURERS OF EPILEPSY DEVICES

Table 7 : MARKET SHARE OF MANUFACTURERS OF FOOT DROP DEVICES

Table 8 : MARKET SHARE OF MANUFACTURERS OF DIABETES/OBESITY DEVICES, 2012

Table 9 : RETINAL DEGENERATION MANUFACTURERS' MARKET SHARE

Table 10 : PREMARKET APPROVALS (PMA) FOR BACK PAIN-ASSOCIATED NEUROSTIMULATION DEVICES

Table 11 : PREMARKET NOTIFICATION (510K) FOR BACK PAIN-ASSOCIATED NEUROSTIMULATION DEVICES

Table 12 : CLINICAL TRIALS FOR BACK PAIN-ASSOCIATED NEUROSTIMULATION DEVICES

Table 13 : CLINICAL TRIALS UNDERWAY FOR CHRONIC MIGRAINE-ASSOCIATED NEUROSTIMULATION DEVICES

Table 14 : PREMARKET APPROVALS (PMA) FOR FAILED BACK SURGERY SYNDROME-ASSOCIATED NEUROSTIMULATION DEVICES

Table 15 : CLINICAL TRIALS FOR FAILED BACK SURGERY SYNDROME-ASSOCIATED NEUROSTIMULATION DEVICES

Table 16 : PREMARKET APPROVALS (PMA) FOR CHRONIC INTRACTABLE PAIN-ASSOCIATED NEUROSTIMULATION DEVICES

Table 17 : CLINICAL TRIALS FOR CHRONIC INTRACTABLE PAIN-ASSOCIATED NEUROSTIMULATION DEVICES

Table 18 : AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 19 : PREMARKET APPROVALS (PMA) FOR PARKINSON'S DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES

Table 20 : CLINICAL TRIALS FOR PARKINSON'S DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES

Table 21 : PATENTS FOR NEUROSTIMULATION AND PARKINSON'S APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 22 : PREMARKET APPROVALS (PMA) FOR DYSTONIA-ASSOCIATED NEUROSTIMULATION DEVICES

Table 23 : CLINICAL TRIALS FOR DYSTONIA-ASSOCIATED DEEP NEUROSTIMULATION DEVICES

Table 24 : NEUROSTIMULATION AND DYSTONIA PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 25 : PREMARKET APPROVALS (PMA) FOR ESSENTIAL TREMOR-ASSOCIATED NEUROSTIMULATION DEVICES

Table 26 : CLINICAL TRIALS FOR ESSENTIAL TREMOR-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES

Table 27 : NEUROSTIMULATION AND ESSENTIAL TREMOR PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 28 : DISTRIBUTION OF DISABILITY-ADJUSTED LIFE YEARS (DALYS) FOR INDIVIDUAL NEUROLOGICAL DISORDERS, INCLUDING EPILEPSY, AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS

Table 29 : DISTRIBUTION OF RANKINGS FOR EPILEPSY BY GLOBAL REGIONS.

Table 30 : GLOBAL PREVALENCE OF EPILEPSY

Table 31 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY, AS A PERCENTAGE OF TOTAL DALYS IN MALES

Table 32 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES

Table 33 : GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY

Table 34 : GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY

Table 35 : GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY

Table 36 : PREMARKET APPROVALS (PMA) FOR EPILEPSY-ASSOCIATED NEUROSTIMULATION DEVICES

Table 37 : PREMARKET NOTIFICATION (510K) FOR EPILEPSY-ASSOCIATED NEUROSTIMULATION DEVICES

Table 38 : CLINICAL TRIALS FOR EPILEPSY-ASSOCIATED NEUROSTIMULATION DEVICES.

Table 39 : CLINICAL TRIALS FOR EPILEPSY-ASSOCIATED VAGAL NERVE NEUROSTIMULATION DEVICES

Table 40 : NEUROSTIMULATION AND EPILEPSY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 41 : DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP IN GLOBAL MALE POPULATION OF 2004

Table 42 : DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP IN GLOBAL FEMALE POPULATION OF 2004

Table 43 : DISTRIBUTION OF RANKINGS FOR SCHIZOPHRENIA BY REGION, 2010

Table 44 : GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS INCLUDING SCHIZOPHRENIA 2010

Table 45 : GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, 2010

Table 46 : GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, 2010

Table 47 : CLINICAL TRIALS FOR SCHIZOPHRENIA-ASSOCIATED NEUROSTIMULATION DEVICES

Table 48 : NEUROSTIMULATION AND SCHIZOPHRENIA PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 49 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING OBSESSIVE-COMPULSIVE DISORDER AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006

Table 50 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING OBSESSIVE-COMPULSIVE DISORDER. AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006

Table 51 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING OBSESSIVE-COMPULSIVE DISORDER, AS A PERCENTAGE OF TOTAL DALYS

Table 52 : DISTRIBUTION OF DALYS FOR OCD IN MALES AS A PERCENTAGE OF TOTAL DALYS ACCORDING TO AGE GROUP, 2006

Table 53 : DISTRIBUTION OF DALYS FOR OCD IN FEMALES AS A PERCENTAGE OF TOTAL DALYS ACCORDING TO AGE GROUP

Table 54 : CLINICAL TRIALS FOR OCD-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES

Table 55 : CLINICAL TRIALS FOR TOURETTE SYNDROME-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES

Table 56 : NEUROSTIMULATION AND OCD PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 57 : GLOBAL PREVALENCE OF ALZHEIMER'S DISEASE, 2006

Table 58 : RANKING OF MORTALITY DUE TO ALZHEIMER'S IN COUNTRIES WITH SIMILAR LEVELS OF HEALTH EXPENDITURE, 2010

Table 59 : GLOBAL DEATHS DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER'S, 2010

Table 60 : GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER'S DISEASE, 2010

Table 61 : GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER'S DISEASE, 2010

Table 62 : CLINICAL TRIALS FOR ALZHEIMER'S DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES

Table 63 : NEUROSTIMULATION AND ALZHEIMER'S PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 64 : CLINICAL TRIALS FOR ANOREXIA NERVOSA-ASSOCIATED DEEP BRAIN NEUROSTIMULATION DEVICES

Table 65 : NEUROSTIMULATION AND ANOREXIA NERVOSA PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 66 : DISTRIBUTION OF RANKINGS FOR BIPOLAR DISORDER BY GLOBAL REGIONS, 2010

Table 67 : GLOBAL PREVALENCE OF BIPOLAR DISORDER, 2004

Table 68 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006

Table 69 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES

Table 70 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, AS A PERCENTAGE OF TOTAL DALYS, 2006

Table 71 : GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, 2010

Table 72 : GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING BIPOLAR DISORDER, 2010

Table 73 : CLINICAL TRIALS FOR BIPOLAR DISORDER-ASSOCIATED NEUROSTIMULATION DEVICES

Table 74 : NEUROSTIMULATION AND BI-POLAR DISORDER PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 75 : DISTRIBUTION OF RANKINGS FOR DEPRESSION BY GLOBAL REGIONS, 2010

Table 76 : GLOBAL PREVALENCE OF DEPRESSION, 2004

Table 77 : GLOBAL DEATHS DUE TO NEUROPSYCHIATRIC DISORDERS INCLUDING DEPRESSION, 2010

Table 78 : GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS INCLUDING DEPRESSION, 2010

Table 79 : GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS INCLUDING DEPRESSION, 2010

Table 80 : PRE-MARKET APPROVALS (PMA) FOR DEPRESSION ASSOCIATED NEUROSTIMULATION DEVICES

Table 81 : CLINICAL TRIALS FOR DEPRESSION ASSOCIATED NEUROSTIMULATION DEVICES

Table 82 : NEUROSTIMULATION AND DEPRESSION PATENTS APPLIED AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 83 : RANK OF MORTALITY DUE TO STROKE IN COUNTRIES WITH SIMILAR LEVELS OF HEALTH EXPENDITURE, 2010

Table 84 : GLOBAL PREVALENCE OF STROKE BY COUNTRY, 2004

Table 85 : CLINICAL TRIALS FOR STROKE-ASSOCIATED NEUROSTIMULATION DEVICES

Table 86 : NEUROSTIMULATION AND STROKE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 87 : TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY ETHNICITY IN THE U.S., FROM 1997 TO 2007

Table 88 : CLINICAL TRIALS FOR TRAUMATIC BRAIN INJURY-ASSOCIATED NEUROSTIMULATION DEVICES

Table 89 : NEUROSTIMULATION AND TRAUMATIC BRAIN INJURY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 90 : CLINICAL TRIALS FOR HEART FAILURE-ASSOCIATED NEUROSTIMULATION DEVICES

Table 91 : NEUROSTIMULATION AND HEART FAILURE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 92 : PRE-MARKET APPROVALS (PMA) FOR GASTRO-ESOPHAGEAL REFLUX DISEASE-ASSOCIATED NEUROSTIMULATION DEVICES

Table 93 : CLINICAL TRIALS FOR GASTRIC DYSMOTILITY-ASSOCIATED NEUROSTIMULATION DEVICES

Table 94 : NEUROSTIMULATION AND GASTRIC DYSMOTILITY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 95 : GLOBAL DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP INCLUDING DIABETES IN THE MALE POPULATION OF 2004

Table 96 : GLOBAL DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP INCLUDING DIABETES, IN THE FEMALE POPULATION OF 2004

Table 97 : PRE-MARKET APPROVALS (PMA) FOR GASTROPARESIS-ASSOCIATED NEUROSTIMULATION DEVICES

Table 98 : CLINICAL TRIALS FOR GASTRIC DYSMOTILITY ASSOCIATED NEUROSTIMULATION DEVICES

Table 99 : NEUROSTIMULATION AND GASTROPARESIS PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 100 : OBESITY IN MALES (>20 YEARS) BY GLOBAL REGION, 2008

Table 101 : OBESITY IN FEMALES (>20 YEARS) BY GLOBAL REGION, 2008

Table 102 : DISTRIBUTION OF OBESITY IN U.S. ADULTS (A) AND MALES (B) AS A PERCENTAGE OF TOTAL POPULATION BY AGE GROUP, 2009 TO 2010

Table 103 : DISTRIBUTION OF OBESITY IN U.S. FEMALES AS A PERCENTAGE OF TOTAL POPULATION, ACCORDING TO AGE GROUP 2009 TO 2010

Table 104 : PERCENTAGE OF OBESITY AMONG MALES (> 20 YEARS) BY INCOME LEVELS AND RACE/ETHNICITY IN U.S., 2005 TO 2008

Table 105 : PERCENTAGE OF OBESITY AMONG FEMALES (> 20 YEARS) BY INCOME LEVELS AND RACE/ETHNICITY IN U.S., 2005 TO 2008

Table 106 : DISTRIBUTION OF OBESITY IN U.S. ADOLESCENTS AND CHILDREN AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2009 TO 2010

Table 107 : DISTRIBUTION OF OBESITY IN U.S. BOYS (2 TO 19 YEARS) AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2009 TO 2010

Table 108 : DISTRIBUTION OF OBESITY IN U.S. GIRLS (2 TO 19 YEARS) AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2009 TO 2010

Table 109 : CLINICAL TRIALS FOR OBESITY-ASSOCIATED NEUROSTIMULATION DEVICES

Table 110 : NEUROSTIMULATION AND OBESITY PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 111 : PRE-MARKET APPROVALS (PMA) FOR OVERACTIVE BLADDER DISORDER-ASSOCIATED NEUROSTIMULATION DEVICES

Table 112 : CLINICAL TRIALS FOR URINARY INCONTINENCE-ASSOCIATED NEUROSTIMULATION DEVICES

Table 113 : NEUROSTIMULATION AND URINARY INCONTINENCE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 114 : PREMARKET APPROVALS (PMA) FOR FECAL INCONTINENCE- ASSOCIATED NEUROSTIMULATION DEVICES

Table 115 : CLINICAL TRIALS FOR FECAL INCONTINENCE ASSOCIATED NEUROSTIMULATION DEVICES

Table 116 : NEUROSTIMULATION AND FECAL INCONTINENCE PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 117 : DISTRIBUTION OF RANKINGS FOR HEARING LOSS BY REGION, 2010

Table 118 : GLOBAL PREVALENCE OF MODERATE OR GREATER HEARING LOSS DISEASE, 2004

Table 119 : GLOBAL PREVALENCE OF MILD OR GREATER HEARING LOSS DISEASE, 2004

Table 120 : LEADING GLOBAL CAUSES OF YEARS LOST DUE TO DISABILITY, INCLUDING HEARING, LOSS IN MALES, 2004

Table 121 : LEADING GLOBAL CAUSES OF YEARS LOST DUE TO DISABILITY INCLUDING HEARING LOSS, IN FEMALES

Table 122 : PREMARKET APPROVALS (PMA) FOR HEARING LOSS-ASSOCIATED NEUROSTIMULATION DEVICES

Table 123 : CLINICAL TRIALS FOR HEARING LOSS-ASSOCIATED NEUROSTIMULATION DEVICES

Table 124 : NEUROSTIMULATION AND HEARING LOSS PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 125 : CLINICAL TRIALS FOR TINNITUS-ASSOCIATED NEUROSTIMULATION DEVICES

Table 126 : NEUROSTIMULATION AND TINNITUS PATENTS APPLIED FOR AND ISSUED FROM 2003 TO NOVEMBER 30, 2013

Table 127 : CLINICAL TRIALS FOR ADAPTIVE NEUROSTIMULATION TECHNOLOGY

 

List of Figures

 

Figure 1 : MARKET SHARE OF CHRONIC PAIN NEUROSTIMULATION DEVICE SALES IN 2012, BY MANUFACTURER

Figure 2 : MARKET SHARE OF HEARING LOSS NEUROSTIMULATION DEVICE SALES IN 2012, BY MANUFACTURER

Figure 3 : SALES DISTRIBUTION OF DIABETES/OBESITY NEUROSTIMULATION DEVICES BY MANUFACTURER, 2012

Figure 4 : DISTRIBUTION OF CHRONIC BACK PAIN INJURY/ILLNESS REQUIRING DAYS MISSED FROM WORK, BY CONDITION

Figure 5 : DISTRIBUTION OF SPRAINS, STRAINS AND TEARS REQUIRING ABSENCES FROM WORK, BY BODY PARTS INCLUDING BACK

Figure 6 : DISTRIBUTION OF BACK INJURY INCIDENT RATES BY AGE GROUP

Figure 7 : DISTRIBUTION OF INCIDENCE RATES OF SORENESS INCLUDING BACK PAIN, BY AGE GROUP

Figure 8 : DISTRIBUTION OF DISABILITY-ADJUSTED LIFE YEARS (DALYS) FOR INDIVIDUAL NEUROLOGICAL DISORDERS INCLUDING MIGRAINE AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS

Figure 9 : DISTRIBUTION OF MIGRAINE INCIDENCE RATES BY AGE GROUP

Figure 10 : GLOBAL PREVALENCE OF PARKINSON'S DISEASE

Figure 11 : NUMBER OF DEATHS GLOBALLY DUE TO INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE

Figure 12 : GLOBAL DEATHS IN MALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE

Figure 13 : GLOBAL DEATHS IN FEMALES DUE TO NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE

Figure 14 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROLOGICAL DISORDERS, INCLUDING PARKINSON'S DISEASE, AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS

Figure 15 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS INCLUDING PARKINSON'S DISEASE AS A PERCENTAGE OF TOTAL DALYS IN MALES

Figure 16 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES

Figure 17 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING PARKINSON'S DISEASE, AS A PERCENTAGE OF TOTAL DALYS

Figure 18 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING EPILEPSY, AS A PERCENTAGE OF TOTAL DALYS

Figure 19 : DISTRIBUTION OF DISABILITY-ADJUSTED LIFE YEARS (DALYS) FOR INDIVIDUAL NEUROLOGICAL DISORDERS AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS, 2006

Figure 20 : GLOBAL PREVALENCE OF SCHIZOPHRENIA, 2004

Figure 21 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006

Figure 22 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006

Figure 23 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING SCHIZOPHRENIA, AS A PERCENTAGE OF TOTAL DALYS, 2006

Figure 24 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER'S DISEASE, AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006

Figure 25 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER'S, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006

Figure 26 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING ALZHEIMER'S DISEASE, AS A PERCENTAGE OF TOTAL DALYS, 2006

Figure 27 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROLOGICAL DISORDERS AS A PERCENTAGE OF TOTAL NEUROLOGICAL DISORDERS, 2006

Figure 28 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING DEPRESSION, AS A PERCENTAGE OF TOTAL DALYS IN MALES, 2006

Figure 29 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS, INCLUDING DEPRESSION, AS A PERCENTAGE OF TOTAL DALYS IN FEMALES, 2006

Figure 30 : DISTRIBUTION OF DALYS FOR INDIVIDUAL NEUROPSYCHIATRIC DISORDERS INCLUDING DEPRESSION AS A PERCENTAGE OF TOTAL DALYS, 2006

Figure 31 : TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION IN MALES AND FEMALES IN THE U.S., 1997 TO 2007

Figure 32 : TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (0 TO 34 YEARS) IN MALES IN THE U.S. FROM 1997 TO 2007

Figure 33 : TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (35-85 YEARS) IN MALES IN THE U.S. FROM 1997 TO 2007

Figure 34 : TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (0 TO 34 YEARS) IN FEMALES IN THE U.S. FROM 1997 TO 2007

Figure 35 : TRAUMATIC BRAIN INJURY DEATHS PER 100,000 POPULATION BY AGE (35 TO 85 YEARS) IN FEMALES IN THE U.S. FROM 1997 TO 2007

Figure 36 : DISTRIBUTION OF PREVALENCE OF HEART FAILURE IN MALES AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2005 TO 2008

Figure 37 : DISTRIBUTION OF PREVALENCE OF HEART FAILURE IN FEMALES AS A PERCENTAGE OF TOTAL POPULATION ACCORDING TO AGE GROUP, 2005-2008

Figure 38 : GLOBAL DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP, INCLUDING CARDIOVASCULAR DISEASE, IN THE MALE POPULATION OF 2004

Figure 39 : GLOBAL DISTRIBUTION OF DEATHS BY LEADING DISORDER CAUSE GROUP, INCLUDING CARDIOVASCULAR DISEASE IN THE FEMALE POPULATION OF 2004

 

 

To order this report: Neurostimulation: Technologies and Global Markets

http://www.reportlinker.com/p02070063/Neurostimulation-Technologies-and-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

 

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, discussed how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a practic...
As software becomes more and more complex, we, as software developers, have been splitting up our code into smaller and smaller components. This is also true for the environment in which we run our code: going from bare metal, to VMs to the modern-day Cloud Native world of containers, schedulers and micro services. While we have figured out how to run containerized applications in the cloud using schedulers, we've yet to come up with a good solution to bridge the gap between getting your contain...
The modern software development landscape consists of best practices and tools that allow teams to deliver software in a near-continuous manner. By adopting a culture of automation, measurement and sharing, the time to ship code has been greatly reduced, allowing for shorter release cycles and quicker feedback from customers and users. Still, with all of these tools and methods, how can teams stay on top of what is taking place across their infrastructure and codebase? Hopping between services a...
Niagara Networks exhibited at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. Niagara Networks offers the highest port-density systems, and the most complete Next-Generation Network Visibility systems including Network Packet Brokers, Bypass Switches, and Network TAPs.
Zerto exhibited at SYS-CON's 18th International Cloud Expo®, which took place at the Javits Center in New York City, NY, in June 2016. Zerto is committed to keeping enterprise and cloud IT running 24/7 by providing innovative, simple, reliable and scalable business continuity software solutions. Through the Zerto Cloud Continuity Platform™, organizations can seamlessly move and protect virtualized workloads between public, private and hybrid clouds. The company’s flagship product, Zerto Virtual...
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service. In his session at 19th Cloud Exp...
For basic one-to-one voice or video calling solutions, WebRTC has proven to be a very powerful technology. Although WebRTC’s core functionality is to provide secure, real-time p2p media streaming, leveraging native platform features and server-side components brings up new communication capabilities for web and native mobile applications, allowing for advanced multi-user use cases such as video broadcasting, conferencing, and media recording.
WebRTC is about the data channel as much as about video and audio conferencing. However, basically all commercial WebRTC applications have been built with a focus on audio and video. The handling of “data” has been limited to text chat and file download – all other data sharing seems to end with screensharing. What is holding back a more intensive use of peer-to-peer data? In her session at @ThingsExpo, Dr Silvia Pfeiffer, WebRTC Applications Team Lead at National ICT Australia, looked at differ...
"Plutora provides release and testing environment capabilities to the enterprise," explained Dalibor Siroky, Director and Co-founder of Plutora, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
Security, data privacy, reliability and regulatory compliance are critical factors when evaluating whether to move business applications from in-house client hosted environments to a cloud platform. In her session at 18th Cloud Expo, Vandana Viswanathan, Associate Director at Cognizant, In this session, will provide an orientation to the five stages required to implement a cloud hosted solution validation strategy.
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and 21st International Cloud Expo, which will take place in November in Silicon Valley, California.
The security needs of IoT environments require a strong, proven approach to maintain security, trust and privacy in their ecosystem. Assurance and protection of device identity, secure data encryption and authentication are the key security challenges organizations are trying to address when integrating IoT devices. This holds true for IoT applications in a wide range of industries, for example, healthcare, consumer devices, and manufacturing. In his session at @ThingsExpo, Lancen LaChance, vic...
SYS-CON Events announced today that delaPlex will exhibit at SYS-CON's @CloudExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. delaPlex pioneered Software Development as a Service (SDaaS), which provides scalable resources to build, test, and deploy software. It’s a fast and more reliable way to develop a new product or expand your in-house team.
Wooed by the promise of faster innovation, lower TCO, and greater agility, businesses of every shape and size have embraced the cloud at every layer of the IT stack – from apps to file sharing to infrastructure. The typical organization currently uses more than a dozen sanctioned cloud apps and will shift more than half of all workloads to the cloud by 2018. Such cloud investments have delivered measurable benefits. But they’ve also resulted in some unintended side-effects: complexity and risk. ...